Nasus Pharma Ltd. (NSRX) Stock Price & Analysis
Nasus Pharma Ltd. (NSRX) — MoonshotScore 48/100 (Fair band), calculated Oct 5, 2026. Price $3.92 (+2.75%), as of the Oct 2, 2026 trading session; market cap $33.8M.
Educational signal · not a buy or sell recommendation · How to read this
Nasus Pharma Ltd. · NSRX
Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company focused on developing intranasal drugs for emergency medical conditions. Their lead products target severe allergies, anaphylaxis, and opioid overdose, utilizing a powder-based intranasal technology for rapid drug absorption.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Nasus Pharma (NSRX)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Strong price action running well ahead of the business — stalling growth underneath; a move to treat with suspicion, not chase. Business Quality: Thin; Financial Safety: Okay; Valuation: Rich; Growth Durability: Shrinking; Momentum: Rising.
- Altman Z 9.43 · Piotroski F 2
Holding back: weak fundamentals, soft growth
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 47 | Fair | |
| 47 | Fair | |
| 47 | Fair | |
| 47 | Fair | |
| 47 | Fair | |
| 47 | Fair |
The score moved from 47 in the stored Oct 4, 2026 snapshot to 48 in the current publication computed Oct 5, 2026 (+1); the largest pillar moves were Growth Durability +1. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $3.92 | |
| Change on the day | +2.75% | |
| 52-week range | $1.98 – $9.50 | |
| Market capitalisation | $33.8M | |
| Shares traded on the day | 28.7K |
Price & events
Other perspectives
Council score for Nasus Pharma (NSRX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 7, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: May 5, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On May 5, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the NSRX film — every key number, told as a short cinematic story
~2 min · open the film
What is Nasus Pharma (NSRX), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Nasus Pharma Ltd. (NSRX) is the company analyzed here. It employs 7 people and is led by Brendan O'Grady. The market values it at $33.8M.
What are the financial strengths and risks for Nasus Pharma (NSRX)?
Short answer
The MoonshotScore pillars rate positive momentum as strengths. What is holding it back is weak fundamentals, soft growth. The distress and quality screens read Altman Z 9.43 · Piotroski F 2. Trailing ratios: earnings yield -4.8%.
What should you watch next at Nasus Pharma (NSRX)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $0.00 · EPS -1.13 · 0 analysts. The stored analyst-target capture is expired, so a current target watchpoint is unavailable.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for NSRX.
Checked against the records this page reads, on the dates shown above.
How does Nasus Pharma compare with its peers?
Short answer
Nasus Pharma's score ranks 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| Nasus Pharma (NSRX) — this page | $3.92 | $33.8M | 48 |
| $2.03 Oct 2, 2026 | $67.4M | 44 5-pillar Oct 5, 2026 | |
| $3.22 Oct 2, 2026 | $28.1M | 39 5-pillar Oct 5, 2026 | |
| $8.50 Oct 2, 2026 | $11.0M | 33 5-pillar Oct 5, 2026 | |
| $1.36 Oct 2, 2026 | $29.1M | 32 5-pillar Oct 5, 2026 | |
| $6.50 Oct 2, 2026 | $60.8M | 29 5-pillar Oct 5, 2026 | |
| $1.99 Oct 2, 2026 | $85.2M | 29 5-pillar Oct 5, 2026 | |
| $0.80 Oct 2, 2026 | $22.4M | 28 5-pillar Oct 5, 2026 | |
| $6.31 Oct 2, 2026 | $25.5M | 27 5-pillar Oct 5, 2026 | |
| $1.01 Oct 2, 2026 | $20.4M | 26 5-pillar Oct 5, 2026 | |
| $3.02 Oct 2, 2026 | $28.0M | 20 5-pillar Oct 5, 2026 | |
| $2.74 Oct 2, 2026 | $133M | 20 5-pillar Oct 5, 2026 | |
| $3.68 Oct 2, 2026 | $9.65M | 19 5-pillar Oct 5, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Last captured analyst target range, low to high (expired, captured Sep 29, 2026)
- $22.00 – $22.00
- Last captured analyst target (expired, captured Sep 29, 2026)
- $22.00
- Last captured median analyst target (expired, captured Sep 29, 2026)
- $22.00
- Revenue estimate
- $0.00
- EPS estimate
- $-1.13
Historical target record · Captured · Capture expired; not a current watchpoint.
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jun 17, 2026
- Transactions
- 2
- Identified insiders
- 1
- Purchases
- 2
- Sales
- 0
- Other transactions
- 0
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Nasus Pharma (NSRX)?
What Investors Ask About Nasus Pharma (NSRX)
These answers are editorial: 1 of these 9 answers is drawn from the NSRX research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for NSRX?
NSRX carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company focused on developing intranasal drugs for emergency medical conditions.
Is NSRX a good stock to buy?
Stock Expert AI does not rate NSRX buy, sell or hold. Nasus Pharma Ltd. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the NSRX stock price today?
The last price recorded on this page for Nasus Pharma Ltd. (NSRX) is $3.92, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the NSRX price target?
The last analyst consensus price target we captured for Nasus Pharma Ltd. (NSRX) was $22.00 (range $22.00 to $22.00, median $22.00), from FMP on Sep 29, 2026. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.
How does Nasus Pharma Ltd. navigate regulatory approval processes?
Nasus Pharma Ltd. navigates regulatory approval processes by adhering to strict guidelines set by regulatory agencies such as the FDA.
What are the key factors to evaluate for NSRX?
Nasus Pharma Ltd. (NSRX) holds a MoonshotScore in the low range. Focus on intranasal drug delivery for emergency medical conditions positions the company in a niche market with the potential for rapid growth. Not financial advice.
How frequently does NSRX data refresh on this page?
NSRX's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven NSRX's recent stock price performance?
Nasus Pharma Ltd. (NSRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary intranasal drug delivery technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NSRX overvalued or undervalued right now?
Nasus Pharma Ltd. (NSRX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (19 figures)
The 19 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 9 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $3.92 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T21:04:47.759Z. | |
px.change | Change on the day | +2.75% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $33.8M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T21:04:46.469Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.105 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 28.7K | FMP | Financial Modeling Prep (FMP) · quote | |
earn.pt_range | Last captured analyst target range, low to high (expired, captured Sep 29, 2026) | $22.00 – $22.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Sep 29, 2026 · Coverage not supplied · Capture expired | |
earn.pt_consensus | Last captured analyst target (expired, captured Sep 29, 2026) | $22.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Sep 29, 2026 · Coverage not supplied · Capture expired | |
earn.pt_median | Last captured median analyst target (expired, captured Sep 29, 2026) | $22.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Sep 29, 2026 · Coverage not supplied · Capture expired | |
own.insiders | Insider transactions via FMP | 2 transactions · 2 purchases, 0 sales, 0 other transactions · 1 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Jun 17, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 8 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.scores | Distress and quality screens | Altman Z 9.43 · Piotroski F 2 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
px.range52 | 52-week range | $1.98 – $9.50 | UNRECORDED | Stored company-profile observation — Captured 2026-09-28 · Expired observation | |
id.employees | Employees | 7 | UNRECORDED | Stored company-profile observation — Captured 2026-09-28 · Expired observation | |
id.ceo | Chief executive | Brendan O'Grady | UNRECORDED | Stored company-profile observation — Captured 2026-09-28 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | earnings yield -4.8% | — | UNRECORDED | Stored key metrics — Date unknown |
earn.estimates | Analyst estimates, next fiscal year | FY2026 revenue $0.00 · EPS -1.13 · 0 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-08-30 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2026 | $0.00 | UNRECORDED | Stored analyst estimates — Captured 2026-08-30 · Expired observation | |
earn.est_eps | EPS estimate, FY2026 | $-1.13 | UNRECORDED | Stored analyst estimates — Captured 2026-08-30 · Expired observation |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 48 of 100 · Fair · pillars 32 / 47 / 39 / 12 / 70 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 47 (stored snapshot Oct 4, 2026) → 48 (current publication computed Oct 5, 2026) (+1) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.